Siemens Healthineers


Reinvested profitability gains boost dynamics towards 2025

22/11/21 -"Healthineers held an impressive virtual investors day when it provided further insights to each division and gave first glimpses of how management thinks the new foursome should work. The most ..."

Pages
66
Language
English
Published on
22/11/21
You may also be interested by these reports :
29/11/21
The higher than anticipated fourth COVID-19 wave (Delta) and the new variant (Omicron) will negatively impact all Fresenius’ divisions, though ...

29/11/21
Against the background of the fast-emerging Omicron SARS CoV-19 variant and the weakening vaccination efficacy, we have lowered our expectations in ...

26/11/21
Given the uncertainties related to sleep apnea devices – also resulting in FDA inspection, remedial actions and litigation/penalty risks, the ...

26/11/21
Given the ongoing supply-chain challenges and re-emerging COVID-19 risks, and despite healthy momentum witnessed across segments, our performance ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO